A Light at the End of the Tunnel: Rebounding Biotech Transactions Provide Hope for Life Sciences Companies

Frank Rahmani, Istvan Hajdu, and Carlton Fleming discuss how there is some light at the end of the tunnel for small and midsized life sciences companies, as the broader biotechnology equity capital markets have rebounded from their more recent lows in June 2022.

They explain how macro conditions, including inflation and higher interest rates, and the perceived impact of regulatory and pricing legislation such as the Inflation Reduction Act, continue to weigh down the life sciences sector and, in particular, the biotechnology subsector. While on a positive note, venture capital investment in emerging life sciences companies, while below the highs of 2020-2021, are still on par with pre-pandemic levels.

View Article